Fast-Acting Nasal Spray for Migraine Snags FDA Approval
The FDA approved intranasal zavegepant (Zavzpret) for acute migraine, making it the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray with this indication, drugmaker Pfizer announced on Friday. Zavegepant is indicated for the treatment of migraine with or without aura, and is not indicated for preventing migraine. The pathophysiology of migraines is related to […]
Intranasal Zavegepant Shows Promise in Acute Migraine
Zavegepant, an investigational nasal spray formulation of a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, met its co-primary endpoints in a phase III randomized placebo-controlled trial of acute migraine. On both primary endpoints — 2-hour pain freedom (23.6% vs 14.9%, P<0.0001) and 2-hour freedom from most bothersome symptom (39.6% vs 31.1%, P=0.0012) — zavegepant was […]
Novel Migraine Prevention Drug Wins FDA Nod
Atogepant (Qulipta) became the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for migraine prevention to win FDA approval, AbbVie announced Monday. The drug earned a nod for prevention of episodic migraine in adults and became the second gepant approved for migraine prevention. The first, rimegepant (Nurtec ODT), originally was approved to […]